



Published in final edited form as:

Nat Immunol. 2013 July ; 14(7): . doi:10.1038/ni.2604.

Compartmentalized and systemic control of tissue immunity by commensals

Yasmine Belkaid and Shruti Naik

Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA

Abstract

The body is composed of various tissue microenvironments with finely tuned local immunosurveillance systems, many of which are in close apposition with distinct commensal niches. Mammals have formed an evolutionary partnership with the microbiota that is critical for metabolism, tissue development and host defense. Despite our growing understanding of the impact of this host-microbe alliance on immunity in the gastrointestinal tract, the extent to which individual microenvironments are controlled by resident microbiota remains unclear. In this Perspective we discuss how resident commensals outside the gastrointestinal tract can control unique physiological niches and the potential implications of the dialog between these commensals and the host for the establishment of immune homeostasis, protective responses and tissue pathology.

Maintenance of tolerance and restoration of host homeostasis after insults or exposure to pathogens relies on complex and coordinated innate and adaptive responses. To this end, specialized populations of cells have to integrate local cues, such as defined metabolites, cytokines or hormones, to induce responses in a way that preserves the physiological and functional requirements of each tissue. To insure these distinct responses, unique subsets of antigen-presenting cells¹⁻⁴, innate lymphoid cells⁵ and stromal cells^{6,7} seed and are locally conditioned by each microenvironment⁸. These tissue-tailored immunological networks are essential for maintaining tissue or exogenous tolerance and the development of appropriate protective and controlled immune responses.

Tissue-specific responses have been particularly explored at barrier tissues such as the lung, skin and the gastrointestinal tract—sites that are constitutively colonized by highly diverse and site-specific flora. Mammals have an evolutionary partnership with the microbiota that is critical for metabolism, tissue development and host defense. In the gastrointestinal tract, part of the local immune response is aimed at maintaining a peaceful coexistence with the resident microbiota. These microbes can in turn control many aspects of both innate and adaptive responses^{9,10}. As such, dysbiosis of the gut microbiota has been associated with severe pathologies ranging from inflammatory bowel diseases to malnutrition^{11,12}. Despite our growing understanding of the complexity and diversity of commensal populations at all barrier sites, such as the skin, the oral cavity and the airways, how tissue-resident microbes outside of the gastrointestinal tract control local and systemic responses remains poorly explored.

Correspondence should be addressed to Y.B. (ybelkaid@niaid.nih.gov).

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Each barrier tissue is a complex and in some cases unstable composite of microbes and host structural, hormonal, nervous and immunological networks, with each of these systems potentially controlled by resident microbiota. Thus, the delicate balance between a healthy or disease state may hinge on discrete interactions that occur between commensals and many host components in a given environment. Based on our understanding of tissue specialization, we could postulate that these unique microbial communities feed into tissue complexity and have coevolved with their host to finely tune the unique requirement of each site. In this Perspective, we will discuss recent evidence linking tissue-resident microbiota and microbe-derived metabolites in the control of local and systemic immune responses and discuss the current gaps in our understanding of these responses.

Distinct anatomical sites have unique commensal communities

Epithelial surfaces sustain diverse communities of commensals that include bacteria, archaea, fungi, protozoa and viruses¹³⁻¹⁷. With an estimated composition of 100 trillion cells, commensals outnumber host cells by at least a factor of ten and encode at least 100-fold more unique genes than their host's genome¹⁸. An appreciation for this complexity was precipitated by recent advances in high-throughput sequencing approaches that uncovered the remarkable diversity of the human microbiota¹⁹⁻²¹. These surveys also unveiled the spatial patterning of the commensal communities in the human body. The gastrointestinal tract is home to the most abundant commensal niche and was the first and most thoroughly examined commensal community in the body²². These studies indicated that Firmicutes and Bacteroidetes are the dominant bacterial phyla of a healthy gut²³. Commensal communities in the intestine are highly sensitive to environmental perturbations caused by host metabolic and inflammatory stress, and dysbiosis in these communities is associated with various disease states²⁴⁻²⁶.

Survey of the flora of 27 different body sites, including the skin, nostril, hair and oral cavity revealed that distinct anatomical sites house unique communities of bacteria and that community structure composition is determined by the ecology of each body site²¹. Similarly, a comparative analysis of the oral and respiratory viromes highlighted the importance of habitat in determining viral composition²⁷. Analysis of the skin, oral cavity, airways, gastrointestinal tract and vagina revealed that each body habitat has distinct dominant bacterial taxa; signature clades identified in each anatomical region of the body were as follows: Actinobacteria, Firmicutes and Proteobacteria dominantly colonize the skin, *Lactobacillus spp.* predominates in the vaginal mucosa, and Bacteroidetes, Firmicutes, Fusobacteria and Proteobacteria prevail in the oral cavity^{28,29}.

Global surveys of the composition of flora highlighted the importance of tissue-specific physical, metabolic and immunological factors in shaping the composition of commensals^{28,29}. The skin, for instance, is a topographically heterogeneous organ that has an abundance of folds and invaginations, such as hair follicles, sebaceous glands and sweat glands, capable of sustaining unique communities of microbes³⁰ (Fig. 1). Characterization of flora from distinct skin sites uncovered niche specialization of the skin microbiome³¹. For instance, *Propionibacterium spp.* can metabolize lipids in sebum and therefore flourish in skin sites enriched in sebaceous glands, *Corynebacterium spp.* inhabit moist sites, and *Proteobacteria spp.* dominated in dry sites³¹. Analysis of microbes from the oral cavity revealed that whereas *Streptococcus spp.* are prevalent in most oral habitats, *Haemophilus spp.* abundantly colonize the buccal mucosa, *Actinomyces spp.* the supragingival plaque and *Prevotella spp.* the subgingival plaque^{29,32}. The airways can also be segregated into distinct ecological regions³³. Although these sites have a homogenous microbial composition, the upper airways have a two- to fourfold greater biomass than the lung and lower respiratory tract^{33,34} (Fig. 1). Although the composition of commensals is likely a major determinant in

the control of each tissue, differences in biomass may also have profound implications in the physiology of the colonized site.

Whereas sequencing of the 16S DNA has allowed for a comprehensive view of human microbial communities, whole-genome shotgun metagenomic sequencing is beginning to inform us of the function of these communities. Metagenomic sequencing has revealed the presence of 'core' pathways that are essential for microbial survival in any environment, such as ribosome and translational machinery, nucleotide charging, and ATP synthesis and glycolysis^{29,35}. Notably, commensal communities are enriched for metabolic capabilities based on the carbohydrate signature of their local microenvironment³⁶. For instance, microbial communities in the oral cavity catabolize simple sugars, intestinal commensals degrade complex polysaccharides and glycogen, and communities in the vagina are enriched in the capacity to degrade peptidoglycan³⁶. As we discuss below, byproducts of these tissue-specific microbial metabolic processes can have a central role in conditioning defined microenvironments.

Bystander control of peripheral tissues by gut commensals

Abundant experimental and clinical data support the idea that commensals residing in the gastrointestinal tract can calibrate both innate and adaptive responses¹⁰. Unique groups of commensals as well as defined byproducts or metabolites of commensals also can have key roles in the control of mucosal responses¹⁰. Additionally, despite being contained by the mucosal firewall⁹, the gut microbiota can also set the tone of immune responses at distal sites in the steady state and during inflammation (Fig. 2). Notably, a decrease in the number of gut commensals via treatment with a broad-spectrum antibiotic resulted in blunted T cell and B cell response to an intranasal infection with the A/PR8 strain of influenza³⁷. This effect of the microbiota is linked to a capacity of microbiota to promote inflammasome-mediated induction of the secretion of interleukin 1 (IL-1) and IL-18³⁷. In this setting, rectal administration of Toll-like receptor (TLR) agonists restored the immune response in antibiotic-treated mice, indicating that either the microbial products can diffuse systemically or that activation of the inflammasome does not need to occur at the site of infection³⁷. Treatment with an antibiotic also impaired adaptive and innate antiviral responses after exposure to systemic lymphocytic choriomeningitis virus and mucosal influenza virus³⁸. Genome-wide transcriptional profiling of macrophages revealed a broad decrease in the expression of genes associated with antiviral immunity³⁸.

In addition to their capacity to promote protective immunity, gut commensals can also influence autoimmune and allergic conditions. Mice lacking intestinal microbiota develop less severe disease in models of arthritis and experimental autoimmune encephalomyelitis^{39,40}. In contrast, colonization with a group of gut commensals, segmented filamentous bacteria, promotes autoimmune arthritis through the induction of antigen-specific interleukin 17-producing T helper cells, which promote production of auto-antibodies via expansion of B cells in germinal centers. Furthermore, recruitment and activation of autoantibody-producing B cells from the endogenous immune repertoire depends on the availability of the target autoantigen and commensal microbiota⁴¹. The commensal microbiota can also decrease inflammation, as colonization of mice with *Bacteroides fragilis* results in the expansion of IL-10-producing regulatory T (T_{reg}) cells, which limit the proinflammatory mechanisms of experimental autoimmune encephalomyelitis in a TLR2-dependent manner³⁹. Additionally, induction of diabetes in the nonobese diabetic mouse model has been linked to the presence of defined intestinal microbes^{42,43}, and signals derived from commensal bacteria can regulate basophil hematopoiesis and consequently allergic inflammation⁴⁴.

This bystander control of peripheral responses can be, at least in part, explained by the unique requirement of the gastrointestinal tract for absorption, resulting in the constant diffusion of a low level of microbial products or metabolites into the bloodstream. For instance, peptidoglycan from radiolabeled *Escherichia coli* can be found in the serum and can improve the killing of *Streptococcus pneumoniae* and *Staphylococcus aureus* by bone marrow–derived neutrophils in a Nod1–dependent manner⁴⁵. Experimental evidence suggests that the diffusion of low amounts of commensal products into the bloodstream can contribute to monocyte exit from the bone marrow at steady-state and alter hematopoiesis⁴⁶. Another example of such communication is the metabolism of dietary fiber by commensal bacteria of the Bacteroidetes phylum into immunomodulatory short-chain fatty acids, such as butyrate and acetate⁴⁷. Binding of these fatty acids to the GPR43 receptor on neutrophils restrains their activation⁴⁷. Consequently, mice lacking GPR43 have augmented inflammatory responses, and exogenous administration of short-chain fatty acids to wild-type mice is clinically beneficial⁴⁷. These data suggest that the constant exposure to low amounts of commensal products and metabolites is critical to functionally tune the peripheral immune system and that subtle changes in this conditioning are likely to have profound consequences on tissue physiology. Nevertheless, although these observations collectively suggest that gut commensals can control the systemic threshold of activation of innate and adaptive cells, these studies cannot exclude a direct role of commensals residing in the lung, skin or other barrier sites in the control of local immunity (Fig. 2). Inflammatory conditions at all barrier sites have been associated with regional perturbations in the indigenous microflora^{48–52}, emphasizing the local role of commensal flora. Below we discuss experimental evidence that supports a role for tissue-resident commensals in the calibration of systemic immunity, regional immunity and inflammation, and highlight the gaps in our current understanding of this control.

Commensals in liver immune function

The liver, although not directly colonized by commensals, is a unique environment in regard to its relationship with the microbiota. This vital organ with a wide range of metabolic functions, including detoxification and production of factors necessary for digestion, receives 80% of its blood from the portal vein, the draining tributary of the intestines, spleen and pancreas. In humans, the entire blood volume circulates through the liver about 360 times per day, and a third of our blood volume passes through the liver each minute⁵³. Consequently, although the liver is not in direct contact with live commensals, its immune function is likely conditioned by its constant exposure to microbe-derived ligands or metabolites⁵⁴. For example, exposure of liver sinusoidal endothelial cells to a low level of lipopolysaccharide results in the loss of TLR4 expression and lipopolysaccharide insensitivity⁵⁵. Although not thoroughly characterized, ligands for TLR9, TLR2 and TLR5 are among the most represented microbial ligands in the portal blood⁵⁶. As such, gut-derived bacterial products control liver-resident dendritic cells by stimulating hepatic IL-6–STAT3 signaling⁵⁶. This signaling inhibits activation and/or maturation of hepatic dendritic cells, elevating the threshold needed for the induction of effector responses⁵⁶. Kupffer cells, the most abundant of all tissue macrophages, reside alongside the sinusoidal endothelium and are the first to encounter commensal products or metabolites. As such, the numbers, functional activity and maturation status of Kupffer cell are directly controlled by the presence of gut flora⁵⁴. In germ-free mice, there are substantially fewer adhesion molecules such as ICAM-1 on liver sinusoidal endothelial cells compared to conventionally raised mice⁵⁴ suggesting that seeding by precursors of Kupffer cells and/or recruitment of other cells may be constitutively controlled by commensal products. Considering our growing understanding of the diversity and abundance of commensal-derived metabolites in the bloodstream, we speculate that the liver is optimally equipped to be conditioned by many microbial signals to maintain its fundamental metabolic function. Further, we propose that

the liver may readily sense subtle alterations in this microbial fingerprinting and translate these changes into alarm responses for the immune system.

Ex vivo analysis of the activation of antigen-presenting cells (APCs) revealed a similar pattern of activation between germ-free and conventionally raised mice in secondary lymphoid organs, including mesenteric lymph nodes^{57,58}, suggesting that under steady-state conditions, the control of activation of APCs may be tissue-specific. However, it is worth noting that the diet of germ-free mice contains microbial ligands that can provide surrogate signals to the ones normally provided by the flora⁵⁹. Coupled with activation induced by tissue dissociation, this is likely to blunt any potential differences resulting from the absence of commensals. A better characterization of the effect of commensals' metabolites and products on resident APCs in distinct tissue is clearly needed.

Skin microbiota in immune responses

The skin, the largest organ of the body, is the primary interface between the host and the environment. Microbial profiling has revealed the presence of highly diverse and specific commensal niches along distinct topographical sites of the skin^{21,31}. Although the skin is a rather inhospitable environment, poor in nutrients, one billion bacteria inhabit a typical square centimeter of human skin, covering the surface and extending down into the appendages such as sebaceous glands and hair follicles⁶⁰. Notably, the hair follicle is a very unique structure, with limited contact with the immune system⁶¹ and capable of orchestrating the organization of the skin immune system in inflammatory settings⁶².

Recent evidence supports the idea that skin microbiota has a fundamental and complex role in the control of skin physiology. Notably, *Staphylococcus epidermidis*, the dominant commensal bacterium found in the skin microflora, produces several antimicrobial proteins and proteases that can limit biofilm formation of pathogenic species⁶³. Gram positive bacteria such as *Lactococcus*, *Streptococcus* and *Streptomyces spp.* also produce factors known as bacteriocins that inhibit the growth of other bacterial strains⁶⁴. In the gastrointestinal tract, commensals have been involved in the induction of antimicrobial proteins such as RegIII⁶⁵. How skin-resident commensals control the host production of antimicrobial proteins remains an open question.

On the one hand, in contrast to the known role of the gut microbiota in promoting the gut associated lymphoid tissue (GALT) development, skin commensals are not required for the seeding of immune cells and overall development of the tissue⁶⁶. On the other hand, the skin-resident bacteria can control fundamental aspects of local immunity and tissue repair. The skin is colonized by various species of *Staphylococcus*, including *S. epidermidis*, that normally reside in contact with keratinocytes. In a setting of skin injury in which pathology is dependent on TLR3, a defined product of this ubiquitous group of bacteria, lipoteichoic acid, can mitigate inflammation in a TLR2-dependent manner⁶⁷. More specifically, lipoteichoic acid suppresses local production of various inflammatory mediators such as IL-6 and tumor necrosis factor (TNF)⁶⁷. Thus, via their capacity to constrain inflammatory responses after tissue injury, defined skin commensal products can limit detrimental inflammatory responses and contribute to wound healing. In contrast, aberrant composition of skin flora or an increase in bacterial load may contribute to failure of tissue repair. Notably, most chronic wounds including diabetic, venous and pressure wounds are characterized by sustained inflammatory responses⁶⁸ and in a mouse model of type 2 diabetes, nonhealing wounds were associated with increased abundance of *Staphylococcus spp.*⁶⁹, highlighting a possible link between bacterial load and local pathologies. Thus, in the context of metabolic syndromes, altered nutrient availability and sustained inflammatory

states could contribute to the emergence and dominance of bacteria that either qualitatively or quantitatively alter the local inflammatory milieu and promote local pathologies.

Skin microbiota also has a nonredundant role in controlling regional immunity (Fig. 2). Skin microbiota directly controls activation of skin-resident lymphocytes at steady state, and in the absence of skin commensals the frequency of Foxp3⁺ T_{reg} cells is dramatically increased⁶⁶. Skin commensals can promote protective immunity to a dermal pathogen, *Leishmania major*³⁷. Thus, commensals in the skin, and potentially at other barrier sites such as the lung or the oral cavity, could act as local adjuvants required to finely tune the activation of effector cells at the site of the response. The action of skin commensals is discrete and specific. As such, skin commensals do not affect the capacity of T cells to be primed or to migrate to the skin but modulate function of dermal T cells by tuning the cutaneous inflammatory milieu. Particularly, skin-resident commensals promote, via mechanisms that remain to be addressed, the production of IL-1 that in turn directly controls the capacity of dermal resident T cells to produce inflammatory cytokines such as interferon (IFN-) and IL-17A³⁷. Of importance, the skin flora controls immune homeostasis and responses to infection in an autonomous manner and independently of the gut flora³⁷. Moreover, the IL-1 pathway is not necessary for the production of inflammatory cytokines by gut-resident T cells⁷⁰. Thus, under steady-state conditions, or in the context of local inflammation, each barrier site is likely to be controlled independently of other commensal niches, and commensals may use unique mechanisms to control each tissue (Fig. 2). This compartmentalization of responses may have evolved as a mechanism to constrain the adjuvant properties of commensals and the unwanted consequences associated with systemic increases in inflammatory responses.

As a corollary of the capacity of the flora to promote local inflammation, clinical reports have implicated skin microbiota in the etiology of cutaneous inflammatory conditions. Disorders such as psoriasis, atopic dermatitis and rosacea are associated with dysbiosis of the skin flora⁷¹. In atopic dermatitis (eczema), a chronic relapsing inflammatory skin disorder, microbial community structures at sites of disease were dramatically altered compared to controls⁷². In patients with atopic dermatitis, the proportion of *Staphylococcus spp.* sequences, and in particular those of *S. aureus*, is greater during disease ‘flares’ and correlated with increased disease severity⁷². Similarly, patients with psoriasis, a chronic T cell-mediated disease affecting 2–3% of the population in the United States and 0.6–1.5% of the population in Europe exhibit a decrease in skin bacterial diversity. Notably, lesional skin from patients with plaque psoriasis is enriched in *Streptococcus spp.* and harbor less *P. acnes* compared to controls⁷³. Mechanistically, skin commensals could contribute to the initiation or amplification of skin pathologies via several mechanisms. Local expansion of unique commensals with enhanced inflammatory potential and/or enrichment in commensal load may trigger aberrant production of antimicrobial peptides, contribute to aberrant keratinocyte proliferation or, as previously discussed, promote the local production of inflammatory mediators³⁷. The IL-1 pathway that is promoted by skin-resident commensals is linked to many chronic inflammatory disorders such as arthritis and asthma, as well as psoriasis and other cutaneous disorders⁷⁴. Psoriatic plaques are also characterized by marked infiltration of activated T cells producing inflammatory cytokines, in particular cytokines of the IL-17 family, such as IL-17A⁷⁵⁻⁷⁷, that have been associated with the pathogenesis of the disease^{78,79}. Some of the pathogenic role of IL-17A results from its capacity to amplify various inflammatory pathways in the skin, leading to hyperproliferation of keratinocytes and formation of lesions in psoriasis^{80,81}. In the context of inflammation, changes in barrier permeability and enhanced contact with commensals could also promote the local inflammatory process. Thus, alterations in the composition or sensing of commensals—via the capacity of commensals to directly and/or indirectly set the threshold of activation of

skin-resident T cells, keratinocytes and APCs—are likely the primary drivers and amplifiers of skin pathologies.

In addition to organ-specific microbiota, dramatic differences in microbial composition exist in each tissue. In humans, skin microbial diversity varies dramatically across various ecological niches⁶⁰. These differences in bacterial composition and/or density may explain why some skin sites are more prone to inflammatory disorders and why severe skin responses in patients with graft versus host disease occur at sites enriched in commensal niches. How indigenous commensal communities control immune cells in distinct ecological niches in a single organ is poorly understood.

Oral microbiota in local immunity

The oral cavity harbors a diverse and complex microbial community that accumulates on both the hard and soft oral tissues in sessile biofilms⁸². Whereas biofilms are extracellular, the oral microbiota also includes communities of intracellular bacteria that invade the gingival and buccal epithelial cells of the mouth. A prominent member of this community is the opportunistic intracellular species, *Porphyromonas gingivalis*, a pathobiont that can behave either as a commensal or pathogen⁸³. Recent evidence suggests that the oral microbiome can control innate host responses of the periodontal tissue and in some settings, contribute to periodontal pathologies⁸⁴. In particular, oral commensals promote the expression of IL-1 protein in the oral mucosa⁸⁴. In contrast, that amount of mRNA encoding IL-1 was not decreased in gingival samples from germ-free mice, suggesting that in the oral cavity commensals may promote inflammasome activity⁸⁴. These results are consistent with the notion that commensal bacteria, in most tissues, can establish a threshold of activation required for immune fitness. As proposed for other barrier sites, commensals can also contribute to tissue pathogenesis. The pathology associated with infection by *P. gingivalis*, a low-abundance oral anaerobic pathogen⁸⁵, relies on the presence of oral microbiota⁸⁶. This species of bacteria, even at very low colonization levels, triggers shifts in the composition of oral microbiota and promotes a substantial increase in the overall abundance of commensal density⁸⁶. During infection by *P. gingivalis*, activation of both the microbiota and the complement cascade are required for bone loss⁸⁶. The mechanism by which oral commensals contribute to this pathology remains unclear, but alteration of commensal populations and increased commensal density have been reported in various settings of barrier inflammation. Acute gastrointestinal infections are often characterized by substantial shifts in the microbiota and dominance of bacteria with enhanced invasive and inflammatory properties⁸⁷⁻⁹⁰. Understanding the key metabolic shift responsible for the emergence of commensals with pathogenic potential in each microenvironment will be central to our understanding of tissue-specific pathology.

Vaginal commensals in immune responses

The human vaginal mucosa, composed of a non-keratinized stratified squamous epithelium, is home to an abundant microflora⁹¹. This highly specialized environment is exposed to foreign substances including spermatozoa and a wide array of pathogens. Adding to this complexity, various parts of the female genital tract are influenced by sex hormones during the menstrual cycle. As such, the vaginal microbial ecosystem undergoes substantial structural changes at various stages in a woman's life⁹¹. In addition, the structure and composition of vaginal microbial communities in healthy women are influenced by natural changes, such as aging, time in the menstrual cycle, menstruation, pregnancy and stress⁹². This implies that the vaginal mucosal innate and adaptive immune system is endowed with the complex task of maintaining the delicate balance between commensal and pathogen across various stages of a woman's life, and induce tolerance required for successful

pregnancy. The commensal microflora is an important component of the vaginal mucosal defense against infections. A key feature of the predominant colonization of the vaginal tract by *Lactobacillus spp* is a relatively low pH, owing to their production of large amounts of lactic acid⁹³. *Lactobacilli* are also thought to contribute to the health of the vagina via the production of H₂O₂, the induction of mucus as well as the direct production of antimicrobial factors⁹⁴. *In vitro* colonization of vaginal epithelial cell multilayers by common vaginal commensals has revealed that these bacteria do not trigger epithelial cells to produce cytokines⁹⁵. Moreover, various isolates of *Lactobacilli* suppress the capacity of epithelial cells to respond to various TLR ligands⁹⁵. Lactic acid is a major product of *Lactobacilli* metabolism⁹⁶. Exposure of peripheral blood mononuclear cells to this metabolite promotes production of IL-23 in response to lipopolysaccharide⁹⁷. In support of a link between vaginal commensals and the local immune responses, vaginal concentrations of IL-1 receptor agonist are elevated in the presence of anaerobic gram negative rods and/or *Gardnerella vaginalis*⁹⁸. It is important to address the role of *Lactobacilli* on the innate and adaptive response of the vaginal environment *in vivo* and the interplay of this control with cyclic hormonal changes.

Airway microbiome in immune responses

The airways can be segregated into distinct ecological regions, which include nasopharynx, oropharynx, upper respiratory tract and lower respiratory tract³³. The epithelial surfaces of the airway contain cilia and are covered by a mucus layer. A feature of the airway is the difference in bacterial density across its length, with the upper airways colonized by the highest load of bacteria^{33,34}. Although the role of the endogenous airway microbiota in the control of local immunity has not been addressed, evidence suggests that local manipulation of the composition of the flora may have profound consequences on the capacity of the host to mount protective responses. In particular, intranasal priming of mice with live or heat-inactivated *Lactobacillus spp.* protects against lethal sequelae infection with the virulent pathogen pneumonia virus of mice. This protective response is associated with diminished expression of proinflammatory cytokines and recovery of less virus^{99,100}. Priming with live *Lactobacilli* results in lower granulocyte recruitment, diminished expression of multiple proinflammatory cytokines (CXCL10, CXCL1, CCL2 and TNF) and recovery of less virus. Notably, protection is not unique to *Lactobacillus spp.* and also has been observed in response to priming with nonpathogenic gram-positive *Listeria spp.*, suggesting that microbial load, rather than specific groups of bacteria may control this adjuvant effect^{99,100}. Of note, this protective effect was independent of TLR signaling, and individual microbial ligands, such as peptidoglycan or bacterial DNA, did not confer protection¹⁰⁰. Along with the studies mentioned above, this highlights our limited understanding of the mechanisms by which commensals control immune functions of tissue.

In germ-free mice, the number of infiltrating T_H2 lymphocytes and eosinophils was higher compared conventionally raised mice, and the composition and status of activation of lung dendritic cells was altered during airway inflammation¹⁰¹. This effect could be reversed by colonization of the mice with the complex commensal flora of conventionally raised mice¹⁰¹. The relative contribution of gut versus lung microbiota to this effect remains to be addressed. A recent comparative microbiome profiling of the sinus of patients and healthy controls revealed lower bacterial diversity in the former, with specific depletion of lactic bacteria and a relative increase in a single species, *Corynebacterium tuberculostearicum*⁴⁹. Experimental approaches in mice have demonstrated that the mucosal microbiota is required to protect against the pathogenic role of *C. tuberculostearicum*⁴⁹. Moreover, *Lactobacillus sakei*, identified in a human cohort of protected patients, antagonized *C. tuberculostearicum* sinus infection, even in the absence of a complete microbiota. These studies suggest that sinus mucosal immune defense is highly dependent

on the composition of the resident microbiota, albeit the mechanism of such control remains to be addressed.

Tissue ‘memory’: long-term consequences of tissue insults

After pathogenic or structural insults, tissues maintain traces or memory that extend beyond adaptive responses of T cells and B cells. These changes include profound structural remodeling, such as scars imposed by excessive fibrotic responses, epigenetic alteration of innate cells and stromal cells as well as modification of the APC network. Additionally, tissue ‘memory’ can also result from long-term alteration of its resident microbiota. A long-term consequence of tissue damage and infection could be the induction of immune responses to commensals. Indeed, during gastrointestinal infections, tolerance to commensals can be lost and microbiota-specific T cells become activated¹⁰². In contrast to steady-state responses to commensal bacteria, during infection commensal-specific T cells, much like pathogen-specific T cells, differentiate to an inflammatory phenotype. In the gastrointestinal tract, these commensal-specific T cells form memory cells that are phenotypically and functionally indistinguishable from pathogen-specific T cells¹⁰². All barrier environments are also primary sites of exposure to pathogens, and sites such as the skin are often subject to barrier breach because of physical damage or infection. These events could lead to enhanced exposure to the microbiota and to immunity to resident commensals at diverse barrier sites. Because of the extraordinary amount of potential antigens expressed by the host microbiota at all body surfaces, this would imply that a substantial fraction of memory cells are expected to be commensal-specific. Such memory cells will develop over time in response to successive infections and/or various barrier breaches. In support of this hypothesis, healthy human serum contains antibodies to skin and intestinal microbiota¹⁰³. Thus, primary exposure to a pathogen in the skin, lung and gastrointestinal tract is likely to occur in the context of a much broader recall response against commensal bacteria. Additional exploration of the memory-cell compartment and the antigen specificity of lymphocytes residing at all barrier sites would inform of the potential impact of these complex responses on tissue physiology and subsequent pathologies. It would be of particular interest to address how responses to conserved bacterial antigens across barrier sites impact local and systemic tissue responses.

Conclusion

Although we could propose that under steady-state conditions or during local inflammatory responses commensals control each tissue in a highly specialized and compartmentalized manner, this regional segregation is likely to be overruled by systemic inflammation (Fig. 2). Low-level diffusion of microbial metabolites to the blood stream and alterations of these signals during pathological states add an additional layer of complexity to our understanding of tissue regulation. The challenge of the next few years will be to devise approaches to explore the complex interplay between these various commensal niches under steady-state conditions and disease states. This will require a better understanding of the keystone bacterial species that control the immune responses at individual sites, and exploration of the mechanisms and cellular target of this control, and an in-depth exploration of the precise mode of interaction between commensals and host cells in their specific ecological niches.

Acknowledgments

This work was supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health. We thank members of the Belkaid laboratory for helpful discussions, particularly S. Spencer and J. Grainger for critical reading of the manuscript.

References


1. Shklovskaya E, et al. Langerhans cells are precommitted to immune tolerance induction. *Proc Natl Acad Sci USA*. 2011; 108:18049–18054. [PubMed: 22006331]
2. Chu CC, et al. Resident CD141 (BDCA3)⁺ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. *J Exp Med*. 2012; 209:935–945. [PubMed: 22547651]
3. Igyarto BZ, et al. Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. *Immunity*. 2011; 35:260–272. [PubMed: 21782478]
4. Scott CL, Aumeunier AM, Mowat AM. Intestinal CD103⁺ dendritic cells: master regulators of tolerance? *Trends Immunol*. 2011; 32:412–419. [PubMed: 21816673]
5. Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. *Annu Rev Immunol*. 2012; 30:647–675. [PubMed: 22224763]
6. Owens BM, Simmons A. Intestinal stromal cells in mucosal immunity and homeostasis. *Mucosal Immunol*. 2013; 6:224–234. [PubMed: 23235744]
7. Malhotra D, Fletcher AL, Turley SJ. Stromal and hematopoietic cells in secondary lymphoid organs: partners in immunity. *Immunol Rev*. 2013; 251:160–176. [PubMed: 23278748]
8. Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. *Nat Rev Immunol*. 2011; 11:221–230. [PubMed: 21350581]
9. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. *Nat Rev Immunol*. 2010; 10:159–169. [PubMed: 20182457]
10. Molloy MJ, Bouladoux N, Belkaid Y. Intestinal microbiota: shaping local and systemic immune responses. *Semin Immunol*. 2012; 24:58–66. [PubMed: 22178452]
11. Blumberg R, Powrie F. Microbiota, disease, and back to health: a metastable journey. *Sci Transl Med*. 2012; 4:137rv137.
12. Smith MI, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. *Science*. 2013; 339:548–554. [PubMed: 23363771]
13. Foulongne V, et al. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. *PLoS ONE*. 2012; 7:e38499. [PubMed: 22723863]
14. Iliev ID, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. *Science*. 2012; 336:1314–1317. [PubMed: 22674328]
15. Reyes A, et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. *Nature*. 2010; 466:334–338. [PubMed: 20631792]
16. Eckburg PB, Lepp PW, Relman DA. Archaea and their potential role in human disease. *Infect Immun*. 2003; 71:591–596. [PubMed: 12540534]
17. Grice EA, Segre JA. The human microbiome: our second genome. *Annu Rev Genomics Hum Genet*. 2012; 13:151–170. [PubMed: 22703178]
18. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell*. 2006; 124:837–848. [PubMed: 16497592]
19. Medini D, et al. Microbiology in the post-genomic era. *Nat Rev Microbiol*. 2008; 6:419–430. [PubMed: 18475305]
20. Kuczynski J, et al. Experimental and analytical tools for studying the human microbiome. *Nat Rev Genet*. 2012; 13:47–58. [PubMed: 22179717]
21. Costello EK, et al. Bacterial community variation in human body habitats across space and time. *Science*. 2009; 326:1694–1697. [PubMed: 19892944]
22. Eckburg PB, et al. Diversity of the human intestinal microbial flora. *Science*. 2005; 308:1635–1638. [PubMed: 15831718]
23. Qin J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010; 464:59–65. [PubMed: 20203603]
24. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. *Nature*. 2012; 489:220–230. [PubMed: 22972295]
25. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. *J Clin Invest*. 2011; 121:2126–2132. [PubMed: 21633181]

26. Tlaskalova-Hogenova H, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. *Cell Mol Immunol.* 2011; 8:110–120. [PubMed: 21278760]
27. Pride DT, et al. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. *ISME J.* 2012; 6:915–926. [PubMed: 22158393]
28. Human Microbiome Project Consortium. A framework for human microbiome research. *Nature.* 2012; 486:215–221. [PubMed: 22699610]
29. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature.* 2012; 486:207–214. [PubMed: 22699609]
30. Grice EA, Segre JA. The skin microbiome. *Nat Rev Microbiol.* 2011; 9:244–253. [PubMed: 21407241]
31. Grice EA, et al. Topographical and temporal diversity of the human skin microbiome. *Science.* 2009; 324:1190–1192. [PubMed: 19478181]
32. Segata N, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. *Genome Biol.* 2012; 13:R42. [PubMed: 22698087]
33. Beck JM, Young VB, Huffnagle GB. The microbiome of the lung. *Transl Res.* 2012; 160:258–266. [PubMed: 22683412]
34. Charlson ES, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. *Am J Respir Crit Care Med.* 2011; 184:957–963. [PubMed: 21680950]
35. Abubucker S, et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. *PLoS Comput Biol.* 2012; 8:e1002358. [PubMed: 22719234]
36. Cantarel BL, Lombard V, Henrissat B. Complex carbohydrate utilization by the healthy human microbiome. *PLoS ONE.* 2012; 7:e28742. [PubMed: 22719820]
37. Ichinohe T, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci USA.* 2011; 108:5354–5359. [PubMed: 21402903]
38. Abt MC, et al. Commensal bacteria calibrate the activation threshold of innate antiviral immunity. *Immunity.* 2012; 37:158–170. [PubMed: 22705104]
39. Ochoa-Reparaz J, et al. Central nervous system demyelinating disease protection by the human commensal *Bacteroides fragilis* depends on polysaccharide A expression. *J Immunol.* 2010; 185:4101–4108. [PubMed: 20817872]
40. Wu HJ, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity.* 2010; 32:815–827. [PubMed: 20620945]
41. Berer K, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. *Nature.* 2011; 479:538–541. [PubMed: 22031325]
42. Wen L, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. *Nature.* 2008; 455:1109–1113. [PubMed: 18806780]
43. Kriegel MA, et al. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. *Proc Natl Acad Sci USA.* 2011; 108:11548–11553. [PubMed: 21709219]
44. Hill DA, et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. *Nat Med.* 2012; 18:538–546. [PubMed: 22447074]
45. Clarke TB, et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. *Nat Med.* 2010; 16:228–231. [PubMed: 20081863]
46. Shi C, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. *Immunity.* 2011; 34:590–601. [PubMed: 21458307]
47. Maslowski KM, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature.* 2009; 461:1282–1286. [PubMed: 19865172]
48. Kong HH, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res.* 2012; 22:850–859. [PubMed: 22310478]


49. Abreu NA, et al. Sinus microbiome diversity depletion and *Corynebacterium tuberculo*stearicum enrichment mediates rhinosinusitis. *Sci Transl Med.* 2012; 4:151ra124.
50. Hilty M, et al. Disordered microbial communities in asthmatic airways. *PLoS ONE.* 2010; 5:e8578. [PubMed: 20052417]
51. Belda-Ferre P, et al. The oral metagenome in health and disease. *ISME J.* 2012; 6:46–56. [PubMed: 21716308]
52. Srinivasan S, et al. Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. *PLoS ONE.* 2010; 5:e10197. [PubMed: 20419168]
53. Crispe IN. The liver as a lymphoid organ. *Annu Rev Immunol.* 2009; 27:147–163. [PubMed: 19302037]
54. Corbitt N, et al. Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. *Am J Pathol.* 2013; 182:180–191. [PubMed: 23159949]
55. Bigorgne AE, Crispe IN. TLRs in hepatic cellular crosstalk. *Gastroenterol Res Pract.* 2010; 2010:618260. [PubMed: 20862346]
56. Lunz JG III, Specht SM, Murase N, Isse K, Demetris AJ. Gut-derived commensal bacterial products inhibit liver dendritic cell maturation by stimulating hepatic interleukin-6/signal transducer and activator of transcription 3 activity. *Hepatology.* 2007; 46:1946–1959. [PubMed: 17935227]
57. Wilson NS, et al. Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling. *Immunol Cell Biol.* 2008; 86:200–205. [PubMed: 18026177]
58. Walton KL, He J, Kelsall BL, Sartor RB, Fisher NC. Dendritic cells in germ-free and specific pathogen-free mice have similar phenotypes and in vitro antigen presenting function. *Immunol Lett.* 2006; 102:16–24. [PubMed: 16105690]
59. Hill DA, et al. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with associated alterations in immune cell homeostasis. *Mucosal Immunol.* 2009; 3:148–158. [PubMed: 19940845]
60. Grice EA, et al. A diversity profile of the human skin microbiota. *Genome Res.* 2008; 18:1043–1050. [PubMed: 18502944]
61. Christoph T, et al. The human hair follicle immune system: cellular composition and immune privilege. *Br J Dermatol.* 2000; 142:862–873. [PubMed: 10809841]
62. Nagao K, et al. Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin. *Nat Immunol.* 2012; 13:744–752. [PubMed: 22729248]
63. Iwase T, et al. *Staphylococcus epidermidis* Esp inhibits *Staphylococcus aureus* biofilm formation and nasal colonization. *Nature.* 2010; 465:346–349. [PubMed: 20485435]
64. Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. *Nat Rev Immunol.* 2012; 12:503–516. [PubMed: 22728527]
65. Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. *Science.* 2006; 313:1126–1130. [PubMed: 16931762]
66. Naik S, et al. Compartmentalized control of skin immunity by resident commensals. *Science.* 2012; 337:1115–1119. [PubMed: 22837383]
67. Lai Y, et al. Commensal bacteria regulate Toll-like receptor 3–dependent inflammation after skin injury. *Nat Med.* 2009; 15:1377–1382. [PubMed: 19966777]
68. Loots MA, et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. *J Invest Dermatol.* 1998; 111:850–857. [PubMed: 9804349]
69. Grice EA, et al. Longitudinal shift in diabetic wound microbiota correlates with prolonged skin defense response. *Proc Natl Acad Sci USA.* 2010; 107:14799–14804. [PubMed: 20668241]
70. Ivanov II, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. *Cell.* 2009; 139:485–498. [PubMed: 19836068]
71. Gallo RL, Nakatsuji T. Microbial symbiosis with the innate immune defense system of the skin. *J Invest Dermatol.* 2011; 131:1974–1980. [PubMed: 21697881]

72. Kong HH, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. *Genome Res.* 2012; 22:850–859. [PubMed: 22310478]
73. Gao Z, Tseng CH, Strober BE, Pei Z, Blaser MJ. Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. *PLoS ONE.* 2008; 3:e2719. [PubMed: 18648509]
74. Sims JE, Smith DE. The IL-1 family: regulators of immunity. *Nat Rev Immunol.* 2010; 10:89–102. [PubMed: 20081871]
75. Nestle FO, Kaplan DH, Barker J. Psoriasis. *N Engl J Med.* 2009; 361:496–509. [PubMed: 19641206]
76. Ortega C, et al. IL-17-producing CD8⁺ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete T_H17-related cytokines. *J Leukoc Biol.* 2009; 86:435–443. [PubMed: 19487306]
77. Eyerich S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. *J Clin Invest.* 2009; 119:3573–3585. [PubMed: 19920355]
78. Leonardi C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. *N Engl J Med.* 2012; 366:1190–1199. [PubMed: 22455413]
79. Papp KA, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. *N Engl J Med.* 2012; 366:1181–1189. [PubMed: 22455412]
80. Zheng Y, et al. Interleukin-22, a T_H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. *Nature.* 2007; 445:648–651. [PubMed: 17187052]
81. Lai Y, et al. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. *Immunity.* 2012; 37:74–84. [PubMed: 22727489]
82. Avila M, Ojcius DM, Yilmaz O. The oral microbiota: living with a permanent guest. *DNA Cell Biol.* 2009; 28:405–411. [PubMed: 19485767]
83. Yilmaz O. The chronicles of *Porphyromonas gingivalis*: the microbium, the human oral epithelium and their interplay. *Microbiology.* 2008; 154:2897–2903. [PubMed: 18832296]
84. Dixon DR, Reife RA, Cebra JJ, Darveau RP. Commensal bacteria influence innate status within gingival tissues: a pilot study. *J Periodontol.* 2004; 75:1486–1492. [PubMed: 15633325]
85. Desvarieux M, et al. Periodontal microbiota and carotid intima-media thickness: the oral infections and vascular disease epidemiology study (INVEST). *Circulation.* 2005; 111:576–582. [PubMed: 15699278]
86. Hajishengallis G, et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. *Cell Host Microbe.* 2011; 10:497–506. [PubMed: 22036469]
87. Egan CE, Cohen SB, Denkers EY. Insights into inflammatory bowel disease using *Toxoplasma gondii* as an infectious trigger. *Immunol Cell Biol.* 2012; 90:668–675. [PubMed: 22064707]
88. Heimesaat MM, et al. Gram-negative bacteria aggravate murine small intestinal Th1-type immunopathology following oral infection with *Toxoplasma gondii*. *J Immunol.* 2006; 177:8785–8795. [PubMed: 17142781]
89. Lupp C, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of *Enterobacteriaceae*. *Cell Host Microbe.* 2007; 2:204. [PubMed: 18030708]
90. Stecher B, et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. *PLoS Biol.* 2007; 5:2177–2189. [PubMed: 17760501]
91. Farage M, Maibach H. Lifetime changes in the vulva and vagina. *Arch Gynecol Obstet.* 2006; 273:195–202. [PubMed: 16208476]
92. Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ. Understanding vaginal microbiome complexity from an ecological perspective. *Transl Res.* 2012; 160:267–282. [PubMed: 22683415]
93. Antonio MA, Hawes SE, Hillier SL. The identification of vaginal Lactobacillus species and the demographic and microbiologic characteristics of women colonized by these species. *J Infect Dis.* 1999; 180:1950–1956. [PubMed: 10558952]
94. Spurbeck RR, Arvidson CG. Lactobacilli at the front line of defense against vaginally acquired infections. *Future Microbiol.* 2011; 6:567–582. [PubMed: 21585263]

95. Rose WA II, et al. Commensal bacteria modulate innate immune responses of vaginal epithelial cell multilayer cultures. *PLoS ONE*. 2012; 7:e32728. [PubMed: 22412914]
96. Zhou X, et al. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. *Microbiology*. 2004; 150:2565–2573. [PubMed: 15289553]
97. Witkin SS, Alvi S, Bongiovanni AM, Linhares IM, Ledger WJ. Lactic acid stimulates interleukin-23 production by peripheral blood mononuclear cells exposed to bacterial lipopolysaccharide. *FEMS Immunol Med Microbiol*. 2011; 61:153–158. [PubMed: 21118312]
98. Genc MR, et al. Polymorphism in intron 2 of the interleukin-1 receptor antagonist gene, local midtrimester cytokine response to vaginal flora, and subsequent preterm birth. *Am J Obstet Gynecol*. 2004; 191:1324–1330. [PubMed: 15507961]
99. Gabryszewski SJ, et al. Lactobacillus-mediated priming of the respiratory mucosa protects against lethal pneumovirus infection. *J Immunol*. 2011; 186:1151–1161. [PubMed: 21169550]
100. Garcia-Crespo KE, et al. Lactobacillus priming of the respiratory tract: Heterologous immunity and protection against lethal pneumovirus infection. *Antiviral Res*. 2013; 97:270–279. [PubMed: 23274789]
101. Herbst T, et al. Dysregulation of allergic airway inflammation in the absence of microbial colonization. *Am J Respir Crit Care Med*. 2011; 184:198–205. [PubMed: 21471101]
102. Hand TW, et al. Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses. *Science*. 2012; 337:1553–1556. [PubMed: 22923434]
103. Haas A, et al. Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection. *Gut*. 2011; 60:1506–1519. [PubMed: 21515549]

**Figure 1.**

Tissue-specific modes of host-commensal interactions at distinct barrier sites. The gastrointestinal tract has the most abundant commensal niches in the body. A thick mucus layer separates the intestinal epithelium from resident microbes. Certain commensal species such as segmented filamentous bacteria (SFB) can penetrate the intestinal mucosal layer and reside in intimate contact with epithelial cells and in Peyer's patches. By virtue of their localization, these species are uniquely poised to influence immune functions. Commensal microorganisms reside on the surface of the skin and appendages, such as hair follicles, sebaceous glands and sweat glands. These appendages may be critical sites of interactions between immune cells and commensals in the skin. The oral cavity contains several microenvironments that house commensal microbes including buccal mucosa, saliva, teeth and gingiva. Individual teeth house bacteria both above and below the gumline, that have been shown to modulate immunity in the surrounding gingiva; additionally, commensal bacteria constitutively form biofilm at this tissue site. In the respiratory tract, the composition of commensals is conserved across different geographical locations but the density of commensals is greatest in the upper airways and is less in the lower airways. The vaginal mucosa is dominantly colonized by *Lactobacillus spp.*, but little is known about the precise localization of commensals in this niche and how fluctuations associated with sexual activity, menstrual cycle and pregnancy impact the microbiota in this site.

**Figure 2.**

Localized and systemic regulation of the immune system by distinct commensal niches. (a) Commensal bacteria in the skin dynamically regulate the cutaneous effector and T_{reg} cells by amplifying inflammatory signals (IL-1). Similarly, commensal signals in the oral mucosa and respiratory tract promote the production of IL-1, and of IL-1 and IL-18, respectively. In the gastrointestinal tract, commensal ligands (TLR, NLR and Nod ligands) and commensal metabolites (short-chain fatty acids) instruct immunity locally. Trace amounts of commensal byproducts enter blood circulation and localize to the bone marrow where they control immune cell development and function. (b) Skin commensals control protective T_H1 responses during a dermal infection in an IL-1–dependent manner. A TLR2 ligand, lipoteichoic acid (LTA) specifically derived from *S. epidermidis* ameliorates exuberant production of TNF and IL-6 during skin inflammation. The signals involved in regulation of intestinal immunity during localized inflammatory responses are similar to those involved in controlling immune homeostasis, but these commensal derived signals are greatly amplified during an inflammatory response. Signals from gut microbiota may diffuse more readily into systemic circulation during gut inflammation. (c) Intestinal microbiota has been identified as a key modulator of systemic immunity. Gut-dwelling commensals can promote pathology in various mouse models of autoimmunity (experimental autoimmune encephalomyelitis (EAE), diabetes and arthritis). The intestinal microbiota also regulates viral immunity in the lung by controlling macrophage responses and inflammasome activation. Allergic airway inflammation is negatively regulated by signals from the flora that down-modulate responses of immune effectors, including production of IgE by plasma cells, development of basophils and accumulation of α NKT in the gut and lung. innate Natural Killer T cells (iNKT), experimental autoimmune encephalomyelitis (EAE), Rheumatoid arthritis (RA),

polysaccharide A(PSA), polymorphonuclear neutrophils (PMN), Peptidoglycan (PGN),
Antimicrobial peptides (AMPs).